

About the Event

The threat of a significant pandemic influenza looms. In late 2005, President Bush outlined his \$7B plan to prepare for a pandemic. The money is now being released to industry. On March 4, 2006, the Department of Health and Human Services awarded over \$1B in contracts to five biopharmaceutical companies to drive new flu vaccine technologies. As a consequence, expectations for the country's pandemic preparedness are rising rapidly. However, delivering on pandemic influenza preparedness will require many additional steps, and the path forward is not yet clear.

End to End Preparedness for Pandemic Influenza: Opportunities for Public-Private Collaboration will bring together senior government officials and top industry executives to explore how an effective partnership between government and industry can be developed to tackle the critical steps in delivering on public health preparedness for pandemic influenza. From *development* to *production* to *supply* to *administration*, these key leaders will examine each step in preparedness to identify the opportunities for strengthening government and industry collaboration and to address the underlying capabilities that must be in place to ensure success. The conference will provide you a unique opportunity to help position your organization in the broad-based effort to deliver on pandemic influenza preparedness.

Pre-Conference Symposium:

Supply Chain Readiness for Pandemic Influenza Response

Speakers representing the three major components of the pandemic response supply chain—production, supply, and administration—will focus on the integration and coordination of key components in the supply chain, highlight any gaps that may exist, and explore strategies for addressing those gaps.

PRE-SORTED
STANDARD
US POSTAGE PAID
ARCADIA, CA
PERMIT NO. 436



Infocast • 6800 Owensmouth Ave., Suite 300 • Canoga Park, CA 91303

DEVELOPMENT PRODUCTION SUPPLY ADMINISTRATION

End to End Preparedness for Pandemic Influenza

Opportunities for Public-Private Collaboration

NOVEMBER 13-15, 2006 • WASHINGTON, DC

Supporting Organizations



Gold Sponsor



Silver Sponsors

Baxter



McKenna Long & Aldridge

Bronze Sponsor



Media Partners

Anti-Infective Drug News

BioExecutive INTERNATIONAL

BioPharm INTERNATIONAL BioProcess INTERNATIONAL BioWORLD TODAY



Drug Delivery Insight

Expert Opinion...



SecurityStockWatch.com
Solutions • Stocks • News

www.infocastinc.com/pand06.html

www.infocastinc.com/pand06.html

End to End Preparedness for Pandemic Influenza

Opportunities for Public-Private Collaboration

NOVEMBER 13-15, 2006 • AED CONFERENCE CENTER • WASHINGTON, DC

Currently Confirmed Participating Organizations:

ASD Healthcare
Baxter Vaccines
Centers for Disease Control and Prevention (CDC)
Cardinal Health, Inc.
Cornell University
Department of Health & Human Services (DHHS)

FFF Enterprises, Inc.
Implicit Bioscience Pty. Ltd.
McKenna Long & Aldridge
MedImmune, Inc.
Novavax Inc.
PRTM Management Consultants

Punk, Ziegel & Company
Roche
Sanofi Pasteur SA
Solvay Pharmaceuticals B.V.
U.S. Food and Drug Administration (FDA)

AGENDA • Tuesday, November 14 - Wednesday, November 15, 2006

Pre-Conference Symposium
Monday, November 13, 2006

Keynote Address:

Congressional Strategy for National Influenza Preparedness

This address will provide a blueprint for Congress's strategy regarding national influenza preparedness, including legislative actions, intended outcomes, progress, expected challenges, and next steps.

Coordinating for Global Preparedness through Public-Private Collaboration

This address will provide an overview of the U.S. government's plans for coordinating with other nations and industry partners in its efforts to deliver on effective pandemic influenza preparedness.

European Perspectives on the Opportunities for Public-Private Collaboration

This session will provide an insight into the European pandemic influenza preparedness efforts, and the opportunities for greater government and industry collaboration.

Emerging Vaccine Technologies' Influence on Pandemic Preparedness

This presentation will focus on the impact of emerging vaccines technologies on government's pandemic influenza preparedness plans.

Evolution of the Pandemic Preparedness Market

This address will focus on the evolution of the government's pandemic preparedness strategy and planning, how it will shape the potential influenza market for vaccines, antivirals, antibiotics, and diagnostics, and the opportunities it will create for companies at all steps of the end to end preparedness framework.

Investing in Development for Pandemic Influenza Preparedness

This panel will review the external funding available for companies developing new technologies and medicines to combat pandemic influenza. Representatives from government, private equity, and venture funds will discuss the outlook for companies seeking funding.

Key Considerations for Production in the Pandemic Setting

This panel will address the key questions in meeting the demands of production during a pandemic, such as what level of surge production capacity will be required, how will the capacity build-out be financed, what is the government's industry policy for pandemic production, and others.

Supplying the Pandemic Market

This panel will focus on the challenges and opportunities in the coordination of the supply chain for pandemic medicines and supplies and what opportunities will exist for industry in the pandemic supply chain.

SUPPLY CHAIN READINESS FOR PANDEMIC INFLUENZA RESPONSE

Introducing an End-to-End Pandemic Preparedness Framework

Session 1: Managing Pandemic Production

This session will focus on the challenges of producing sufficient quantities of vaccines and therapeutics once a pandemic is declared. It will address such questions as: How will influenza strains be selected for vaccine production in a pandemic? How will industry quickly formulate pandemic vaccines and ramp up production? How will they determine the right scale?

Session 2: Managing Pandemic Supply

This session will cover the distribution of medicines and supplies and will highlight the critical need for coordination of the chain. Speakers from government and industry will address the following issues: How will stockpiles and total vaccine supplies be managed and maintained? How will medicines and supplies be delivered? How will areas of needs for medicine be prioritized? Who will make necessary decisions regarding possible early supply gaps?

Session 3: Managing Pandemic Administration

This session will focus on managing a pandemic from the public health infrastructure perspective. It will address issues such as: How will the hospital and clinic infrastructure manage an intense surge in demand for care? How will public health authorities ensure that patient needs are met in administering medicines and providing supportive care? How will the safety of care givers be ensured?